Standard Biotools (LAB) Income from Discontinued Operations (2024 - 2026)

Standard Biotools (LAB) has reported Income from Discontinued Operations for 3 consecutive years, with -$5.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Income from Discontinued Operations rose 66.85% year-over-year to -$5.2 million in Q2 2026; TTM through Jun 2026 was $138.8 million, a 557.21% increase from a year earlier, with the FY2025 full-year figure at -$16.1 million, up 66.48% from the prior year.
• Income from Discontinued Operations was -$5.2 million for Q2 2026 at Standard Biotools, down from $141.7 million in the prior quarter.
• Over five years, Income from Discontinued Operations peaked at $141.7 million in Q1 2026 and troughed at -$20.3 million in Q2 2024.
• A 3-year average of $9.8 million and a median of -$5.0 million in 2024 frame the typical range for Income from Discontinued Operations.
• Across the five-year window, Income from Discontinued Operations increased 22.14% in 2025 and surged 5420.84% in 2026, its largest moves.
• Over 3 years, Income from Discontinued Operations stood at -$6.9 million in 2024, then surged by 178.01% to $5.4 million in 2025, then tumbled by 197.23% to -$5.2 million in 2026.
• The last three Income from Discontinued Operations figures came in at -$5.2 million (Q2 2026), $141.7 million (Q1 2026), and $5.4 million (Q4 2025), per Business Quant data.